WallStSmart

Edwards Lifesciences Corp (EW)vsReWalk Robotics Ltd (LFWD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Edwards Lifesciences Corp generates 29743% more annual revenue ($6.51B vs $21.82M). EW leads profitability with a 15.4% profit margin vs -141.3%. EW earns a higher WallStSmart Score of 55/100 (C).

EW

Buy

55

out of 100

Grade: C

Growth: 4.0Profit: 8.0Value: 5.3Quality: 8.5
Piotroski: 3/9Altman Z: 4.48

LFWD

Avoid

34

out of 100

Grade: F

Growth: 7.3Profit: 2.0Value: 5.0Quality: 4.5
Piotroski: 4/9Altman Z: -18.73
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

EWUndervalued (+68.9%)

Margin of Safety

+68.9%

Fair Value

$254.99

Current Price

$84.37

$170.62 discount

UndervaluedFair: $254.99Overvalued

Intrinsic value data unavailable for LFWD.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EW3 strengths · Avg: 9.3/10
Debt/EquityHealth
0.0710/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.4810/10

Safe zone — low bankruptcy risk

Operating MarginProfitability
29.8%8/10

Strong operational efficiency at 29.8%

LFWD2 strengths · Avg: 8.0/10
Price/BookValuation
1.6x8/10

Reasonable price relative to book value

Revenue GrowthGrowth
15.7%8/10

15.7% revenue growth

Areas to Watch

EW4 concerns · Avg: 2.8/10
PEG RatioValuation
1.924/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

P/E RatioValuation
51.6x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-25.4%2/10

Earnings declined 25.4%

LFWD4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$20.11M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-209.1%2/10

ROE of -209.1% — below average capital efficiency

Free Cash FlowQuality
$-6.00M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : EW

The strongest argument for EW centers on Debt/Equity, Altman Z-Score, Operating Margin. Profitability is solid with margins at 15.4% and operating margin at 29.8%. Revenue growth of 13.6% demonstrates continued momentum.

Bull Case : LFWD

The strongest argument for LFWD centers on Price/Book, Revenue Growth. Revenue growth of 15.7% demonstrates continued momentum.

Bear Case : EW

The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 51.6x leaves little room for execution misses.

Bear Case : LFWD

The primary concerns for LFWD are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

EW profiles as a mature stock while LFWD is a growth play — different risk/reward profiles.

EW carries more volatility with a beta of 0.85 — expect wider price swings.

LFWD is growing revenue faster at 15.7% — sustainability is the question.

EW generates stronger free cash flow (585M), providing more financial flexibility.

Bottom Line

EW scores higher overall (55/100 vs 34/100), backed by strong 15.4% margins and 13.6% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Edwards Lifesciences Corp

HEALTHCARE · MEDICAL DEVICES · USA

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.

Visit Website →

ReWalk Robotics Ltd

HEALTHCARE · MEDICAL DEVICES · USA

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes robotic exoskeletons for individuals with mobility impairments or other medical conditions in the United States, Europe, the Asia-Pacific, and Africa. The company is headquartered in Yokneam Illit, Israel.

Want to dig deeper into these stocks?